NCT05544214

Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD 371 in Healthy Subjects

An Open Label, Randomized, Single Dose Crossover Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD 371 in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: Chong Kun Dang Pharmaceutical · Industry
• Sex: All
• Age: 19 Years – 45 Years
• Healthy volunteers: Accepted

Summary

This study is an open-label, randomized, single dose, crossover study to evaluate the pharmacokinetics, safety and tolerability of CKD-388 in healthy subjects

Detailed description

To healthy 32 subjects, following treatments are administered dosing in each period and wash-out period is a minimum of 7 days. Reference drug: D745, D759 / Test drug: CKD-371 Pharmacokinetic blood samples are collected up to 48hrs. The pharmacokinetic characteristics and safety are assessed.

Conditions

• Type II Diabetes Mellitus

Interventions

Type	Name	Description
DRUG	CKD-371	PO

Timeline

• Start date: 2022-10-21
• Primary completion: 2022-11-14
• Completion: 2022-11-17
• First posted: 2022-09-16
• Last updated: 2023-03-22

Locations

1 site across 1 country: South Korea